Latest TSHA reports update at 2024-05-14: 2024-Q1 ∙ 2023-Q4 ∙ 2023-Q1

Taysha Gene Therapies TSHA

$ 2.53 6.3%

Taysha Gene Therapies Financial Statements 2011-2024 | TSHA

Annual Financial Statements Taysha Gene Therapies

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	261 M	30.3 M	240 M	305 M	-	-	-	-	-	-	-	-	-
Shares	116 M	44 M	37.7 M	11.7 M	-	-	-	-	-	-	-	-	-
Historical Prices	2.25	0.69	6.37	25.6	-	-	-	-	-	-	-	-	-
Net Income	-112 M	-166 M	-175 M	-60 M	-	-	-	-	-	-	-	-	-
Revenue	15.5 M	2.5 M	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-72.4 M	-162 M	-173 M	-43 M	-	-	-	-	-	-	-	-	-
Interest Expense	5 M	3.8 M	1.43 M	28 K	-	-	-	-	-	-	-	-	-
EBITDA	-71.1 M	-161 M	-173 M	-43 M	-	-	-	-	-	-	-	-	-
Operating Expenses	87.9 M	165 M	173 M	43 M	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	30 M	37.4 M	41.3 M	11.1 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Taysha Gene Therapies

	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	231 M	187 M	126 M	64.2 M	63.3 M	63.2 M	40.9 M	40.1 M	38.2 M	38.5 M	38 M	37.5 M	37 M	37.8 M	11.7 M	10.9 M	10.9 M	9.63 M	8.72 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-24.1 M	-	-117 M	-24.6 M	-17.6 M	-	-26.5 M	-34.1 M	-50.3 M	-	-51.2 M	-40.9 M	-32 M	-	-15 M	-21.2 M	-5.43 M	-1.12 M	-31 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	3.41 M	-	4.75 M	2.4 M	4.71 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-24.3 M	-	-16.2 M	-23.4 M	-16.6 M	-	-25.5 M	-33.4 M	-49.7 M	-	-50.7 M	-40.8 M	-32.1 M	-	-15 M	-4.01 M	-5.58 M	-1.12 M	-31 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	29 K	-	1.47 M	1.44 M	1.37 M	-	1.08 M	743 K	672 K	-	543 K	194 K	-	-	1 K	27 K	27 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-24 M	-	-16 M	-23 M	-16.2 M	-	-25.2 M	-33.1 M	-49.4 M	-	-50.5 M	-40.7 M	-32.1 M	-	-15 M	-4.01 M	-5.58 M	-1.12 M	-31 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	27.7 M	-	21 M	25.8 M	21.3 M	-	25.5 M	33.4 M	49.7 M	-	50.7 M	40.8 M	32.1 M	-	15 M	4.01 M	5.58 M	1.12 M	31 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	7.08 M	-	8.59 M	5.99 M	8.75 M	-	8.68 M	9.87 M	11.5 M	-	11.2 M	10.1 M	8.24 M	-	3.98 M	948 K	70 K	128 K	31 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency